-- Vioxx 25 mg was superior to celecoxib 200 mg and acetaminophen
4,000 mg at relieving pain at rest; patients taking Vioxx 25 mg
experienced an average reduction of 31.1 mm on the WOMAC Index versus
an average reduction of 23.4 mm among celecoxib patients and an
average reduction of 21.7 mm among acetaminophen patients.
Similar results were reported on the measures that assessed early efficacy
(the first six days of therapy) with Vioxx 25 mg, celecoxib 200 mg and
acetaminophen 4,000 mg.
In addition, significantly more patients taking Vioxx 25 mg daily reported
a good or excellent response to treatment at six weeks than patients taking
celecoxib 200 mg or acetaminophen 4,000 mg; 60.2 percent of patients taking
Vioxx 25 mg reported a good or excellent response to therapy at week six
versus 45.7 percent of patients taking celecoxib and 39.1 percent of patients
Vioxx 12.5 mg and celecoxib 200 mg were not statistically different from
each other on any measure in early efficacy or at six weeks.
All treatments studied were generally safe and well-tolerated. There were
no significant differences in the incidence of any clinical adverse events
between the groups.
Vioxx, a prescription medicine that selectively inhibits the COX-2 enzyme,
is approved in the United States for the relief of the signs and symptoms of
osteoarthritis, management of acute pain in adults and treatment of menstrual
pain. Celecoxib also selectively inhibits COX-2. Acetaminophen is a widely
used pain reliever.
The recommended starting dose of Vioxx for the treatment of osteoarthritis
is 12.5 mg once daily. Some patients may receive additional benefit by
increasing the dose to 25 mg once daily, the maximum recommended dose for
Serious stomach problems, such as bleeding, can occur without warning
symptoms. Physicians and patients should remain alert for signs and symptoms
of gastrointestinal bleeding.
People who have had an allergic reaction to Vioxx, aspirin or other NSAIDs
should not take Vioxx. Safety and effectiveness in children below the age of
18 have not been studied. Common side effects reported in other clinical
trials with Vioxx were upper-respiratory infection, diarrhea, nausea and high